recall
saveEndo USA, Inc. recall (Cls III)
November 5, 2025updated 5mo ago
community read0 votes
Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-119-91 — Reason: Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C. — Status: Ongoing
view source ↗Data sources
last refreshed 52m ago
Found something off?
same company · ±60 days · 6
- recallEndo USA, Inc. recall (Cls III)Nov 5, 2025
- recallEndo USA, Inc. recall (Cls III)Nov 5, 2025
- recallEndo USA, Inc. recall (Cls III)Nov 5, 2025
- approvalKETALAR (KETAMINE HYDROCHLORIDE) — FDA approvalOct 29, 2025
- recallEndo USA, Inc. recall (Cls III)Oct 22, 2025
- approvalALVIMOPAN — FDA approvalSep 23, 2025
🐶 often sniffed alongside
top 8- tagEndocrinology & Metabolism10 co-mentions · 10 sources
- tagRecall10 co-mentions · 10 sources
- drugeverolimus SR5 co-mentions · 5 sources
- drugEVEROLIMUS5 co-mentions · 5 sources
- drugeverolimus ODT5 co-mentions · 5 sources
- drugZortress5 co-mentions · 5 sources
- drugEPIPEN E Z PEN4 co-mentions · 1 sources
- drugEPINEPHRINE4 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that